Intuitive Surgical Launches New da Vinci System to Drive Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Technology Launch: Intuitive Surgical's latest da Vinci system features Force Feedback Technology, enabling surgeons to better sense pressure on patients' tissues during procedures, which is expected to enhance surgical outcomes and drive demand from healthcare providers and consumers.
- Market Expansion Potential: The company recently received approvals for three new indications, which will help boost its procedure volume and drive revenue growth, showcasing a strong outlook in the robotic-assisted surgery sector.
- Pricing Power to Address Challenges: Despite facing cost pressures from tariffs, Intuitive Surgical possesses pricing power, allowing for modest price increases to mitigate profit and margin impacts, thereby maintaining its competitive edge in the market.
- Competitive Landscape Analysis: While Medtronic's Hugo system has gained U.S. approval, the underpenetrated robotic-assisted surgery market provides ample room for Intuitive Surgical to continue growing, with expectations to outperform broader market trends in the coming years.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 612.47 USD with a low forecast of 440.00 USD and a high forecast of 700.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
16 Buy
3 Hold
1 Sell
Strong Buy
Current: 572.630
Low
440.00
Averages
612.47
High
700.00
Current: 572.630
Low
440.00
Averages
612.47
High
700.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
